BC Extra | Jul 1, 2019
Company News

Management Tracks: BioCryst hires its first CBO; plus ObsEva, Veracyte and more

Rare disease company BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) hired Megan Sniecinski as its first CBO. She was SVP of business operations and program management at PTC Therapeutics Inc. (NASDAQ:PTCT). Reproductive health company ObsEva S.A. (NASDAQ:OBSV; SIX:OBSN)...
BC Extra | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin...
BC Week In Review | Jan 18, 2019
Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
BC Innovations | Jun 28, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Conjugates Hafnium (Hf)-based metal-organic complexes could enhance the sensitivity of solid tumors to radiotherapy. The complexes consist of nanoscale frameworks of six or 12 Hf atoms coordinated to molecules of 2,5-di( p -benzoato)aniline (DBA),...
BC Week In Review | Jun 22, 2018
Clinical News

Nanobiotix’s NBTXR3 meets in Phase II/III for STS

Nanobiotix S.A. (Euronext:NANO) said NBTXR3 (PEP503) met the primary and secondary endpoints in the Phase II/III act.in.sarc trial to treat locally advanced soft tissue sarcoma. The compound comprises crystalline nanoparticles of hafnium oxide activated in...
BC Extra | Jun 21, 2018
Clinical News

Nanobiotix’s NBTXR3 meets in Phase II/III for STS

Nanobiotix S.A. (Euronext:NANO) said NBTXR3 met the primary and secondary endpoints in the Phase II/III act.in.sarc trial to treat locally advanced soft tissue sarcoma. The compound comprises crystalline nanoparticles of hafnium oxide activated in vivo...
BC Extra | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

An industry party held during the BIO annual meeting in Boston has been excoriated by the trade organization for featuring nude or partially clothed female dancers. The trade organization’s chairman called on the party’s sponsors...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 3, 2017
Financial News

Nanobiotix raises EUR27.2M

On Oct. 31, cancer company Nanobiotix S.A. (Euronext:NANO) raised €27.2 million ($31.6 million) through the sale of 1.9 million shares at €14 in a placement. The price is a 22% discount to the company’s close...
Items per page:
1 - 10 of 55
BC Extra | Jul 1, 2019
Company News

Management Tracks: BioCryst hires its first CBO; plus ObsEva, Veracyte and more

Rare disease company BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) hired Megan Sniecinski as its first CBO. She was SVP of business operations and program management at PTC Therapeutics Inc. (NASDAQ:PTCT). Reproductive health company ObsEva S.A. (NASDAQ:OBSV; SIX:OBSN)...
BC Extra | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin...
BC Week In Review | Jan 18, 2019
Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
BC Innovations | Jun 28, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Conjugates Hafnium (Hf)-based metal-organic complexes could enhance the sensitivity of solid tumors to radiotherapy. The complexes consist of nanoscale frameworks of six or 12 Hf atoms coordinated to molecules of 2,5-di( p -benzoato)aniline (DBA),...
BC Week In Review | Jun 22, 2018
Clinical News

Nanobiotix’s NBTXR3 meets in Phase II/III for STS

Nanobiotix S.A. (Euronext:NANO) said NBTXR3 (PEP503) met the primary and secondary endpoints in the Phase II/III act.in.sarc trial to treat locally advanced soft tissue sarcoma. The compound comprises crystalline nanoparticles of hafnium oxide activated in...
BC Extra | Jun 21, 2018
Clinical News

Nanobiotix’s NBTXR3 meets in Phase II/III for STS

Nanobiotix S.A. (Euronext:NANO) said NBTXR3 met the primary and secondary endpoints in the Phase II/III act.in.sarc trial to treat locally advanced soft tissue sarcoma. The compound comprises crystalline nanoparticles of hafnium oxide activated in vivo...
BC Extra | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

An industry party held during the BIO annual meeting in Boston has been excoriated by the trade organization for featuring nude or partially clothed female dancers. The trade organization’s chairman called on the party’s sponsors...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 3, 2017
Financial News

Nanobiotix raises EUR27.2M

On Oct. 31, cancer company Nanobiotix S.A. (Euronext:NANO) raised €27.2 million ($31.6 million) through the sale of 1.9 million shares at €14 in a placement. The price is a 22% discount to the company’s close...
Items per page:
1 - 10 of 55